- Protease Scoreboard
Planning for Efficacy Rates of 30-50%, Roche Protease Trials Shoot for Distant Stars
- The Imperiled NCDDG
Twilight of NIH Drug Discovery Program Will Mean Even Slimmer Pickings for AIDS Therapeutic Pipeline
- Random Gleanings
Vaccine Victory (Of Sorts), Inching Closer To An Animal Model for HIV, G.D. Searle's lead protease inhibitor crashed and burned...
- Interleukin-2: An Update
Ten Years On, Feckless IL-2 Researchers Plod Ahead, Certain Of Success
- ACTG: Re-competition Blues
Dazed and Confused, ACTG "Re"-Competitors Ready Themselves For The 1996-2001 Funding Cycle
- Yokohama: Malignancy Reportage
Brouhaha Over Human Chorionic Gonadotropin (hCG) Yields, Again, To Sober Realism
- Star Gazing at the FDA
Public Hearings At FDA Juxtapose Old Cries of Access With Those of Integrity, Accountability
- Yokohama Pathogenesis Update
Improved Clinical Outcomes Wrought By Immunosuppressive Medicine and Second-Rate Immune Responses - Where Will It All End?
- The KS Project Report
Research Paper Details Advances, Obstacles In The Treatment of Kaposi's Sarcoma
- Merck's Protease Plans
Shot Down Early On, Merck Scientists Test Higher Doses And Combinations, Hoping for Success
- When (Not) To Start ARV Therapy
Yokohama Roundtable Examines Treatment Quandary Facing Patients, Clinicians Alike
- Shift Rift
Series of Research Papers Take To Task Would-Be Discoverers Of Cytokine Switch Scrutinizing the Knock-out Mice
- Looking Where the Light Is
Garbage In, Garbage Out; Could It Be We're Asking Good Questions Of Bad Systems?
- Letter From Rockville
Another meeting with the (FDA) Commissioner, Rockville, MD, 11 July 1994
- Not So Fast!
With Its First Protease Trial Completed, Roche Races to FDA With Lukewarm Results, While Activists Cry 'Foul'
- Vaccine Dismay
NIAID Scraps Large Scale Vaccine Trial -- And A Chastened Genentech Takes Its Case to The Hill
- ACTG Rescue Plan
Tome of Recommendations Would Abolish ACDDC, Mandate Costing-Out and Establish Advisory Review Group
- A Word About TAG
Information about TAG
- Feet to the Fire
ACTG Investigators Scramble to Convince Industry They Can Produce
- Inter-Company Cahoots
ICC's Brainchild Designed to Show Every Drug and Every Combination a Success. Who Could Complain About That?
- Stavudine for Everyone
Accelerated Approval Guidelines Expedite Bristol's Launch of New Nucleoside -- In the Absence of Any Proof That It Works
- Lesion Liberation Unlikely
KS Proves Formidable Foe As Angiogenesis Inhibitors and Stealth Chemotherapy Fall Short of Expectations
- The Protease Quandary
One Company's Search for an Effective Antiviral Contrasts Another's Scramble for the Easy Money
- Vexed Virologists
Study After Study, Antiretroviral Analyses Confound More Than They Clarify